Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lexaria Attending “Partnership Opportunities in Drug Delivery” Next Week
Please see Lexaria’s Events tab on their website.
This could be a good time for announcing any Pharma deals in my opinion.
Partnership Opportunities in Drug Delivery (PODD) is offered as a virtual program and promises to uphold its ten year tradition of combining partnering with access to cutting-edge business and scientific content in the field of drug delivery with loyal support from a top notch speaking faculty. PODD offers access to a wide range of drug delivery technologies and opens partnering before during and after the event.
About PODD
Pharma, biotech and the drug delivery industries gather annually at PODD to assess delivery needs, latest trends and information on deals and learn about a wide range of innovative drug delivery technologies that could improve the delivery of various types of drugs. This can include proteins, peptides, oligonucleotides, biologics, and small molecules and more. PODD provides business development opportunities through organized networking and a partnering tool for new, emerging and established collaborations.
Someone just bought 10,000 LEXXW warrants
JAZZ mentioned as possible ideal Partner with Lexaria in Zack’s Recent Research Report
https://scr.zacks.com/news/news-details/2021/LEXX-Lexarias-DehydraTECH-Shows-Fast-Delivery-/default.aspx
Zacks Small-Cap Research analysts recently announced coverage of Lexaria based on its market potential, valuing the company at $15 per share.
Lexaria’s patented DehydraTECH(TM) technology is undergoing clinical and pre-clinical trials for potential use in treating hypertension, viral infections, and other conditions that are currently being addressed through cannabidiol-based nutraceuticals or prescription drugs
DehydraTECH and big Pharma
Lets get this straight no other company that I am aware of has ever produced the type of fast action delivery in oral form of nicotine, cbd, antivirals or hypertension medicine.
Fertin pharma has never achieved the results Lexaria has. No pharma has to my knowledge.
DehydraTECH is the real deal.
Show us what other pharma has published results that has achieved DehydraTECH’s recently published results.
Hey Pfizer
How about recharging your Viagra sales with DehydraTECH?
Pfizer’s CEO would be a fool if he did not at least explore DehydraTECH to boost Viagra sales that were over a $1 billion not that long ago in the US. Viagra sales are still $500 million or so in the US.
That is just one drug my fellow shareholders that potentially will benefit immensely from DehydraTECH.
Time to Load Up on DehydraTECH
I sense enormous opportunities.
Delisting in Canada
What a non event.
Sell your shares on the Canadian exchange and buy them back on NASDAQ.
Lets face it the NASDAQ is where the huge institutional money is.
DehydraTECH International Future
There is a confluence of events that should ignite DehydraTECH around the world.
1. Covid and the need for antiviral oral drugs instead of a needle administered by a nurse
2. Nicotine delivery via oral ingestion instead of frying your lungs
3. CBD delivered orally that reduces stress in minutes not a half hour
4. Viagra and equivalents that deliver results in minutes not a half hour later
DehydraTECH international is a billion dollar company one day in my opinion. A billion dollar market cap equates to $200 a share. That is the potential upside.
Think of just this one dream
Viagra powered by DehydraTECH
No 30 minute wait men.
Also the cost of each pill may drop dramatically
Based on the most efficient and effective
Drug delivery System for certain oral drugs
Ever invented in my opinion.
Imagine This
Remedesivir Powered by DehydraTECH
Oral Nicotine Powered by DehydraTECH
Viagra Powered by DehydraTECH
Just these three drugs would likely result in hundreds of millions of revenue.
Who on earth wishes to wait 30 minutes to feel the effects of Viagra, or Nicotine or Remedesivir?
DehydraTECH is the future.
Why are we calling Our Company Lexaria Bioscience?
Dump that name, shed that snake skin, and rename Lexy
“DehydraTech”
Your market cap will likely increase substantially in my opinion.
I use to work for one of the largest investment banks in the world and the present name is a 2 on a scale of 1 to 10.
Dream Pharma Deal
Just dreaming here Chris
Lexy secures a 10 percent investment from a billion dollar market cap Pharmaceutical company and provides exclusivity rights to to use DehydraTECH for a specific market segment such as Covid.
This is the “Big Bang” your shareholders are seeking.
If you need an example of a technology company that has no revenues and a market cap of $675 million look at the stock symbol LOOP and how they partnered with a giant to advance their technology today.
I own shares in LOOP and in my opinion DehydraTECH has even more potential. LOOP is a Canadian company. If Lexy had a $675 million market the share price would be over $125 a share.
Come on Chris get a deal done.
How about a New Pharma License Agreement Chris Bunka?
It cannot be that hard with your R and D results. Maybe you need a new VP of Sales that can close a deal with big pharma.
$10 Next Stop
Lexy is setting up for a move into the double digits over the next week or two.
Dear Chris Bunka
Outstanding results from your R and D efforts will only get you so far. You need to hire a VP of Sales that has extensive experience with closing deals with big pharma and you need to open an office either in New York or San Francisco.
Hiding out in Kelowna is a great idea after you retire. Time to get serious now.
And how about dropping Bioscience from Lexy’s name. You are a technology company that licenses a revolutionary way of delivering drugs to patients effectively, efficiently and profitably.
Lexy Gross Profit is Over 80 Percent
See last 10Q.
A hypothetical $100,000,000 in sales equates to $80,000,000 in gross profit if that gross margin was maintained. That equates to about $16,000 of gross margin per share.
Lexy is like a software company, it is a licensor of technology to licensees.
Just One Licensing Agreement Possibly = A Few Hundred Million in Revenue
The markets Lexy is addressing are multi billion dollar markets. You will never see Lexy stock in the single digits again if they succeed.
Licensing Deal on Horizon
In my opinion DehydraTECH is revolutionary and will disrupt how we take pharmaceutical drugs for decades. We need a licensing deal with a Fortune 500 Pharmaceutical company to the light the fire on this rocket ship.
Patience will be rewarded.
Mergers and Acquisitions in Sector
Has anyone even noticed the acquisitions going on in the sector?
Think about this.
How much is Lexy’s Drug Delivery Technology worth to Pfizer or Jazz or .........
Lexy is the Amazon of Drug Delivery Technology
Amazon is essentially a delivery company of products.
Lexy has the potential in my opinion to be the Amazon of delivering drugs effectively, efficiently and profitably.
Lexy is a Drug Delivery Technology Company
Forget the bioscience.
We shareholders own a revolutionary technology company.
Top five antihypertensive drugs market vendors (per Bloomberg)
One of these giants may be interested in Lexy and its technology.
AstraZeneca
AstraZeneca operates through the segment, biopharmaceuticals. The company’s
key offerings include DUTOPROL, ZESTORETIC, and ZESTRIL.
Johnson & Johnson Services, Inc.
Johnson & Johnson Services, Inc. runs its operations through three segments:
consumer, pharmaceutical, and medical devices. The company’s key offerings
include: OPSUMIT, TRACLEER, UPTRAVI, VELETRI, and VENTAVIS.
Merck & Co., Inc.
Merck & Co., Inc. runs its operations through two segments: pharmaceutical and
other. The company’s key offerings include COZAAR, HYZAAR, and PRINIVIL.
Novartis AG
Novartis AG runs its operations through three segments: innovative medicines,
sandoz, and alcon. The company’s key offerings include DIOVAN, DIOVAN HCT,
ENTRESTO, EXFORGE HCT, and LOTREL.
Pfizer Inc.
Pfizer Inc. runs its operations through two segments: innovative health and
essential health. The company’s key offerings include ACCURETIC, NORVASC, and
REVATIO.
Treat Lexx Investment like an Option
The upside versus downside on this stock is astronomical.
Any Lexy Shareholders Remember the Old Days?
The closes were powerful in the early days of this stock years ago.
Lexy was a star a couple of years ago.
Hold on for the ride.
The upside is off the charts on this stock in my opinion.
Anyone Notice the Close Today
That was a serious buyer with balls.
Funny how the whiners have disappeared.
Lexy is a Pharmaceutical Company
Mark my words a Fortune 500 pharmaceutical company will buy Lexy one day in my opinion for a 100 times more than its current market price.
Interesting How the Whiners Disappeared Today
Today was a warning shot of what is to come.
Be Patient.
2021 is our year my friends.
Stop Whining LXRP shareholders
Lets see what happens in 2021.
Bottoms occur based on the volume of whining whimps
On every blog I have seen.
I feel we are near a bottom.
I believe in Bunka and his team.
Go Lexy.
Stop Whining and Watch What Unfolds over 2021
We are not alone. Be brave.
Go Lexxy Go.
Revenues up 500 percent from Same Period Last Year
The 10Q was filed this morning. This is going to be an exciting year for Lexy.
Pharmaceutical News Cycle Starts in May and runs through Year End 2021
Enjoy these low prices while you can.
GW Pharmaceuticals and Lexaria
GW is the most obvious potential pharmaceutical partner for Lexaria (market cap $29 million). GW has a market cap of $6.5 billion and has the resources to utilize this technology on multiple fronts immediately.
Pharmaceutical Deal Pipeline 2021
Surely Lexaria has been in talks with large Pharmaceutical entities with any deals contingent on the current trials.
If the trials are successful and even one deal is closed the stock will skyrocket. NDAs will not allow Bunka to disclose any deals at this point.
Now is the time to buy in my opinion.
All the Garbage Posts are Buyers of Lexx
Bunka is the real deal.
He has held his position and increased it despite the obscenely low prices over the last year.
Relax, close your eyes and never sell to the bullshitters.
Lift off is Near
Charts matter and I like what I see here.
The Fun is Just Beginning
Last time I posted Lexy was in the mid 4s.
Imagine just one possible deal with a Pfizer or Merck and what would happen to this tiny float...
Lexy is a Life Changing Stock
The bottom is in my fine friends.
Hold on for the ride.
I Love the Pessimism
That is how bottoms are formed.
Time to Load the Truck with LEXY
I have been following this stock as long as anybody and I am loading up the truck.